869899-30-9

Upstream product

• 155417-78-0 (3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 869899-29-6 1,2,4,6-tetra-O-acetyl-3-(3,5-dimethoxybenzamido)-3-deoxy-D-galactopyranose 

Downstream Products

• 869899-31-0 bis(2,4,6-tri-O-acetyl-3-deoxy-3-(3,5-dimethoxybenzamido)-β-D-galactopyranosyl) sulfane 
• 1041009-55-5 1-(S)-acetyl-2,4,6-tri-O-acetyl-3-deoxy-3-(3,5-dimethoxybenzamido)-1-thio-β-D-galactopyranose 

Relevant academic research and scientific papers

Double affinity amplification of galectin-ligand interactions through arginine-arene interactions: Synthetic, thermodynamic, and computational studies with aromatic diamido thiodigalactosides

A series of aromatic monoor diamido-thiodigalactoside derivatives were synthesized and studied as ligands for galectin-1, -3, -7, -8N terminal domain, and -9N terminal domain. The affinity determination in vitro with competitive fluorescence-polarization

C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: Efficient lectin inhibition through double arginine-arene interactions

Inhibitors of galectin-3, which has been implicated in cancer- and immunity-related processes, can be synthesized from thiodigalactoside derivatives with aromatic amide substituents at both C3 positions (see structure). Dissociation constant (Kd/sub

NOVEL GALACTOSIDE INHIBITORS OF GALECTINS

The present invention relates to novel galactosides and the use of the galactosides as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. Said galectin is preferably galectin-3.